Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 162-166

  Korst, Annelies E C ^a   Gall, Helen E ^a   Vermorken, Jan B ^a   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amifostine; Ascites; Disulfides; Pharmacokinetics; WR 1065

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; CARBOPLATIN; DEXAMETHASONE; DRUG METABOLITE; ONDANSETRON; THIETHYLPERAZINE MALEATE;

AGED; ARTICLE; ASCITES CELL; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TISSUE LEVEL; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; VOMITING;

ADENOCARCINOMA; AMIFOSTINE; ASCITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISULFIDES; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MERCAPTOETHYLAMINES; MIDDLE AGED; RADIATION-PROTECTIVE AGENTS; STOMACH NEOPLASMS;

EID: 0029822506     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050553     Document Type: Article

References (12)

1. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR 1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 47: 23-27
2. Fleckenstein L, Swynnerton NF, Ludden TM, Mangold DJ (1988) Bioavailability and newer methods of delivery of phosphorothioate radioprotectors. Pharmacol Ther 39: 203-212
3. Korst AEC, Snel J, Kedde MA, Van der Vijgh WJF (1995) A sensitive HPLC-ECD assay for amifostine and its metabolites in plasma. Proc Int Symp Column Chromatogr Rel Tech 19: 225
4. Korst AEC, Kedde MA, Eeltink CM, Vermerken JB, Van der Vijgh WJF (1995) Pharmacokinetics of amifostine in plasma and ascites of patients. Proc Am Assoc Cancer Res 36: 291
5. Shaw LM, Turrisi AT, Glover DJ, et al (1986) Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12: 1501-1504
6. Shaw LM, Glover D, Turrisi A, et al (1988) Pharmacokinetics of WR-2721. Pharmacol Ther 39: 195-201
7. Shaw LM, Bonner HS, Brown DQ (1994) Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 22: 895-902
8. Tanaka Y (1984) Clinical experiences with a chemical radioprotector in tumor radiotherapy: WR-2721. In: Sugahara T (ed) Modification of radio sensitivity in cancer treatment. Academic Press, Tokyo, pp 61-81
9. Treskes M, Nijtmans LG, Fichtinger-Schepman AMJ, et al (1992) Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethylcarbamate. Biochem Pharmacol 43: 1013-1019
10. Treskes M, Boven E, Van de Loosdrecht AA, et al (1994) Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30A: 183-187
11. Utley JF, Seaver N, Newton GL, Fahey RC (1984) Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 10: 1525-1528
12. Yuhas JM (1980) Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)ethylphosphorothioic acid. Cancer Res 40: 1519-1524